The FDA’s Center For Drug Evaluation and Research (CDER) has released its annual ‘Accelerating Rare Disease Cures (ARC) Program’ report for 2024.
Since its launch in 2022, the CDER’s ARC programme has become a key resource for the rare disease community and a driver of innovative approaches for rare disease drug development.